Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Osteoporosis 6Prostatic Neoplasms 4Bone Diseases, Metabolic 4Breast Neoplasms 3Triple Negative Breast Neoplasms 1Prostatic Hyperplasia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteoporosis, Postmenopausal 1Lymphoma 1Lung Neoplasms 1Leukemia 1Dwarfism, Pituitary 1

Interventions

Radiotherapy 2polyphenon E 1mirabegron 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Transurethral Resection of Prostate 1Transurethral Resection of Bladder 1Therapeutics 1Tamsulosin 1Risedronic Acid 1Prostatectomy 1Prostate-Specific Antigen 1Papaverine 1Oxygen 1Nitrous Oxide 1Needles 1Microspheres 1Levofloxacin 1Electroacupuncture 1Dutasteride 1Doxazosin 1Diclofenac 1Dexmedetomidine 1Cystoscopy 1Celecoxib 1Catheters, Indwelling 1Botulinum Toxins, Type A 1Blood Specimen Collection 1Amyloid 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Prostatic Hyperplasia × Risedronic Acid × Clear all
NCT00426777 2012-02-03

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

CMX Research

Phase 3 Completed
160 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡